Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 9/20 | 0.42 |
| ▸ | SCN1A | P35498 | 7/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | PDE9A | O76083 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8095793 | 0.93 | SCN8A (0.46) | HCRTR1HCRTR2SCN8ASCN1AHRH3 | |
| SCHEMBL5532351 | 0.91 | HCRTR1 (0.44) | HCRTR1HCRTR2SCN8ASCN1APDE9A | |
| SCHEMBL5528217 | 0.81 | HRH3 (0.52) | HCRTR1HCRTR2HRH3CYP2D6 | |
| SCHEMBL5532322 | 0.77 | SLC2A1 (0.45) | HCRTR1HCRTR2HRH3 | |
| SCHEMBL5532956 | 0.76 | MCHR1 (0.53) | HCRTR1HCRTR2SCN8ASCN1APIK3CD | |
| SCHEMBL5531767 | 0.74 | HCRTR1 (0.51) | HCRTR1HCRTR2HTTALDH1A1MAPT | |
| SCHEMBL5532963 | 0.74 | NCF1 (0.58) | HRH3 | |
| SCHEMBL5532160 | 0.74 | HTR1D (0.44) | HCRTR1HCRTR2HRH3 | |
| SCHEMBL5528119 | 0.73 | ADAM17 (0.44) | HCRTR1HCRTR2HRH3 | |
| SCHEMBL8100066 | 0.72 | ROCK1 (0.53) | HCRTR1HCRTR2MCHR1CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | HCRTR1 887/4885HCRTR2 374/4885SCN8A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.